Detail akcie Vivoryon Ther Br Rg online

Business Summary: Vivoryon Therapeutics NV is a Germany-based biopharmaceutical company focused on discovering, developing, and potentially commercializing small molecule-based medicines that modulate the activity and stability of pathologically altered proteins. The Company has established a pipeline of orally available small molecule inhibitors for various indications, focused on oral small molecule-based therapeutics with a differentiated mode of action for treating diseases with inflammatory and/or fibrotic components, such as chronic diseases of the kidney or liver. It focuses on chronic kidney disease (CKD), and more precisely- are initially targeting stage 3b and worse diabetic kidney disease (DKD). In addition to developing small molecule-based medicines, the Company is also pursuing antibody-based approaches for Alzheimer’s disease (AD).
Financial Summary: BRIEF: For the six months ended 30 June 2025, Vivoryon Therapeutics NV revenues was not reported. Net loss decreased 60% to EUR5.5M. Lower net loss reflects Research and development expenses decrease of 73% to EUR2.8M (expense), General and administrative expenses decrease of 21% to EUR2.8M (expense), Foreign exchange expense decrease of 97% to EUR1K (expense).